Search Results | Cancer Research | American Association for Cancer Research

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Abstract 3341: Synthetic lethality by targeting ribonucleotide reductase in PP2A deficient uterine serous carcinoma

Caitlin M. O'Connor, Sarah E. Taylor, Kathryn M. Miller, Lauren Hurst, Terrance J. Haanen, Tahra K. Suhan, Kaitlin P. Zawacki, Fallon K. Noto, Jonida Trako, Arathi Mohan, Jaya Sangodkar, Dmitriy Zamarin, Analisa DiFeo, Goutham Narla

Cancer Res (2022) 82 (12_Supplement): 3341.

DOI: https://doi.org/10.1158/1538-7445.AM2022-3341

Published: 15 June 2022

View article

Journal Articles

Abstract P1-02-10: Breast tumor measurement after neoadjuvant chemotherapy using the 8^th edition of the American Joint Committee on cancer staging system: Impact on estimates of tumor size and discrepancies with residual cancer burden class

Dawn Harter, Siobhan M O'Connor, Johann D Hertel, Benjamin C Calhoun

Cancer Res (2022) 82 (4_Supplement): P1-02-10.

DOI: https://doi.org/10.1158/1538-7445.SABCS21-P1-02-10

Published: 15 February 2022

View article

Journal Articles

Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma

Cancer Res (2022) 82 (4): 721–733.

DOI: https://doi.org/10.1158/0008-5472.CAN-21-1987

Published: 17 December 2021

View article

Includes: Supplementary data

Journal Articles

Abstract 2981: Biased activation of PP2A through selective heterotrimer binding and stabilization

Daniel Leonard, Wei Huang, Sudeh Izadmehr, Caitlin M. O'Connor, Danica D. Wiredja, Zhizhi Wang, Nilesh Zaware, Daniela M. Schlatzer, Stefan Schuchner, Janna Kiselar, Yinghua Chen, Nikhil Vasireddi, Abbey L. Perl, Matthew D. Glasky, Wenqing Xu, David L. Brautigan, Egon Ogris, Derek J. Taylor, Goutham Narla

Cancer Res (2020) 80 (16_Supplement): 2981.

DOI: https://doi.org/10.1158/1538-7445.AM2020-2981

Published: 15 August 2020

View article

Journal Articles

The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis

Cancer Res (2019) 79 (16): 4242–4257.

DOI: https://doi.org/10.1158/0008-5472.CAN-19-0218

Published: 15 August 2019

View article

Includes: Supplementary data

Journal Articles

Abstract P4-16-08: A regional audit of 6-hour monitoring for administration related reactions during the first administration of subcutaneous trastuzumab

S Karmali, N Hughes, A Kinneally, J Kroes, J Cook, M Killian, T Shafiq, D O'Mahony, B Bird, M O'Connor, S O'Reilly, R Galiauskas, CG Murphy

Cancer Res (2019) 79 (4_Supplement): P4-16-08.

DOI: https://doi.org/10.1158/1538-7445.SABCS18-P4-16-08

Published: 15 February 2019

View article

Journal Articles

Abstract PD4-05: Molecular breast imaging and tomosynthesis to eliminate the reservoir of undetected cancer in dense breasts: The Density MATTERS trial

D Rhodes, K Hunt, A Conners, S Zingula, D Whaley, R Ellis, J Gasal Spilde, R Mehta, M-Y Polley, M O'Connor, C Hruska

Cancer Res (2019) 79 (4_Supplement): PD4-05.

DOI: https://doi.org/10.1158/1538-7445.SABCS18-PD4-05

Published: 15 February 2019

View article

Journal Articles

Abstract P6-08-17: Pregnancy associated breast cancer: Evaluating maternal outcomes. A multicentre study

Cancer Res (2018) 78 (4_Supplement): P6-08-17.

DOI: https://doi.org/10.1158/1538-7445.SABCS17-P6-08-17

Published: 15 February 2018

View article

Journal Articles

Abstract 2646: Intratumoral delivery of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, inhibits tumor growth and prolongs animal survival in a subcutaneous B cell lymphoma model

Gloria H. Lin, Marilyse Charbonneau, Vien Chai, Alison M. O'Connor, Bolette Bossen, Hui Chen, Mark Wong, Natasja N. Viller, Emma Linderoth, Lisa D. Johnson, Xinli Pang, Jeffery Winston, Penka S. Petrova, Robert A. Uger

Cancer Res (2017) 77 (13_Supplement): 2646.

DOI: https://doi.org/10.1158/1538-7445.AM2017-2646

Published: 01 July 2017

View article

Journal Articles

Abstract OT3-02-07: A phase II study to compare fulvestrant (F) 500mg plus placebo versus (vs) F 500mg plus palbociclib (P) as first line treatment for postmenopausal women with hormone receptor (HR)-positive advanced breast cancer (BC) sensitive to endocrine therapy (ET). “The FLIPPER study” (GEICAM/2014-12)

F Moreno, N Martínez-Jañez, I Garau, JA Guerra, J Alarcón, B Bermejo, L Gonzalez-Cortijo, C Bueno, J Lao, S Bezares, L Rosell, A Blanch, R Caballero, E Carrasco, F Rojo, M Martín, M O'Connor, A Hernando, J Albanell

Cancer Res (2017) 77 (4_Supplement): OT3-02-07.

DOI: https://doi.org/10.1158/1538-7445.SABCS16-OT3-02-07

Published: 15 February 2017

View article

Journal Articles

Abstract OT3-04-03: The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland

NM Keegan, M Milewski, CM Kelly, V Murphy, C Chao, J Walsh, MJ Kennedy, M O'Connor, C Murphy, S O'Reilly, M Keane, K Duffy, B Hennessy, PG Morris

Cancer Res (2017) 77 (4_Supplement): OT3-04-03.

DOI: https://doi.org/10.1158/1538-7445.SABCS16-OT3-04-03

Published: 15 February 2017

View article

Journal Articles

Abstract 5583: Integrative genomic analyses on pediatric acute myeloid leukemia

Cancer Res (2014) 74 (19_Supplement): 5583.

DOI: https://doi.org/10.1158/1538-7445.AM2014-5583

Published: 01 October 2014

View article

Journal Articles

Abstract P4-12-25: Randomized phase II study of pre-operative docetaxel, carboplatin with trastuzumab (TCH) and/or/lapatinib (L) in HER-2 positive (H+) breast cancer patients (BC pts). ICORG 10-05

J Crown, L Coate, M Keane, J Kennedy, S O'Reilly, C Kelly, M O'Connor, M Martin, K Duffy, C Murphy, J Walshe, T O'Shea, B Moulton, K Egan, N O'Donovan, G Gullo, K Geraghty, B Hennessy

Cancer Res (2013) 73 (24_Supplement): P4-12-25.

DOI: https://doi.org/10.1158/0008-5472.SABCS13-P4-12-25

Published: 15 December 2013

View article

Journal Articles

Abstract 2811: Vitamin K intake and risk of non-Hodgkin lymphoma (NHL)

James R. Cerhan, Helen M. O'Connor, Zachary S. Fredericksen, Mark Liebow, William R. Macon, Alice H. Wang, Clive S. Zent, Stephen M. Ansell, Susan L. Slager, Timothy G. Call, Thomas M. Habermann

Cancer Res (2010) 70 (8_Supplement): 2811.

DOI: https://doi.org/10.1158/1538-7445.AM10-2811

Published: 15 April 2010

View article

Journal Articles

A Small-Molecule Inhibitor of Bcl-X_L Potentiates the Activity of Cytotoxic Drugs In vitro and In vivo

Cancer Res (2006) 66 (17): 8731–8739.

DOI: https://doi.org/10.1158/0008-5472.CAN-06-0367

Published: 01 September 2006

View article

Includes: Supplementary data

Journal Articles

The Bcl-2 inhibitor ABT-737 shows significant anti-tumor efficacy in a model of non-Hodgkin’s B cell lymphoma

Michael J. Mitten, Anatol Oleksijew, Jessica Powlas, Jacqueline M. O’Connor, Baole Wang, Scott Akler, Mary Joseph, Haichao Zhang, Paul Nimmer, Milan Bruncko, Shichung Ng, Andrew Wei, David Wang, Christin Tse, Steven W. Elmore, Tilman Oltersdorf, Saul Rosenberg, David J. Frost, Alex R. Shoemaker

Cancer Res (2005) 65 (9_Supplement): 399–400.

Published: 01 May 2005

View article

Journal Articles

ABT-737: A small molecule inhibitor of Bcl-2 with dramatic anti-tumor activity in xenograft models of small cell lung cancer

Cancer Res (2005) 65 (9_Supplement): 400.

Published: 01 May 2005

View article

Journal Articles

A p21^Waf1/Cip1 Carboxyl-terminal Peptide Exhibited Cyclin-dependent Kinase-inhibitory Activity and Cytotoxicity When Introduced into Human Cells

Masato Mutoh, Feng-Di T. Lung, Ya-Qiu Long, Peter P. Roller, Robert S. Sikorski, Patrick M. O’Connor

Cancer Res (1999) 59 (14): 3480–3488.

Published: 01 July 1999

View article

Journal Articles

Characterization of the p53 Tumor Suppressor Pathway in Cell Lines of the National Cancer Institute Anticancer Drug Screen and Correlations with the Growth-Inhibitory Potency of 123 Anticancer Agents

Patrick M. O'Connor, Joany Jackman, Insoo Bae, Timothy G. Myers, Saijun Fan, Masato Mutoh, Dominic A. Scudiero, Ann Monks, Edward A. Sausville, John N. Weinstein, Stephen Friend, Albert J. Fornace, Jr., Kurt W. Kohn

Cancer Res (1997) 57 (19): 4285–4300.

Published: 01 October 1997

View article

Journal Articles

Abrogation of an S-Phase Checkpoint and Potentiation of Camptothecin Cytotoxicity by 7-Hydroxystaurosporine (UCN-01) in Human Cancer Cell Lines, Possibly Influenced by p53 Function

Rong-Guang Shao, Chun-Xia Cao, Tsunehiro Shimizu, Patrick M. O'Connor, Kurt W. Kohn, Yves Pommier

Cancer Res (1997) 57 (18): 4029–4035.

Published: 01 September 1997

View article

NARROW

Abstract 3341: Synthetic lethality by targeting ribonucleotide reductase in PP2A deficient uterine serous carcinoma

Abstract P1-02-10: Breast tumor measurement after neoadjuvant chemotherapy using the 8^th edition of the American Joint Committee on cancer staging system: Impact on estimates of tumor size and discrepancies with residual cancer burden class

Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma

Abstract 2981: Biased activation of PP2A through selective heterotrimer binding and stabilization

The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis

Abstract P4-16-08: A regional audit of 6-hour monitoring for administration related reactions during the first administration of subcutaneous trastuzumab

Abstract PD4-05: Molecular breast imaging and tomosynthesis to eliminate the reservoir of undetected cancer in dense breasts: The Density MATTERS trial

Abstract P6-08-17: Pregnancy associated breast cancer: Evaluating maternal outcomes. A multicentre study

Abstract 2646: Intratumoral delivery of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, inhibits tumor growth and prolongs animal survival in a subcutaneous B cell lymphoma model

Abstract OT3-04-03: The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland

Abstract 5583: Integrative genomic analyses on pediatric acute myeloid leukemia

Abstract P4-12-25: Randomized phase II study of pre-operative docetaxel, carboplatin with trastuzumab (TCH) and/or/lapatinib (L) in HER-2 positive (H+) breast cancer patients (BC pts). ICORG 10-05

Abstract 2811: Vitamin K intake and risk of non-Hodgkin lymphoma (NHL)

A Small-Molecule Inhibitor of Bcl-X_L Potentiates the Activity of Cytotoxic Drugs In vitro and In vivo

The Bcl-2 inhibitor ABT-737 shows significant anti-tumor efficacy in a model of non-Hodgkin’s B cell lymphoma

ABT-737: A small molecule inhibitor of Bcl-2 with dramatic anti-tumor activity in xenograft models of small cell lung cancer

A p21^Waf1/Cip1 Carboxyl-terminal Peptide Exhibited Cyclin-dependent Kinase-inhibitory Activity and Cytotoxicity When Introduced into Human Cells

Characterization of the p53 Tumor Suppressor Pathway in Cell Lines of the National Cancer Institute Anticancer Drug Screen and Correlations with the Growth-Inhibitory Potency of 123 Anticancer Agents

Abrogation of an S-Phase Checkpoint and Potentiation of Camptothecin Cytotoxicity by 7-Hydroxystaurosporine (UCN-01) in Human Cancer Cell Lines, Possibly Influenced by p53 Function

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only